The beneficial effects of chronic statin treatment are not mediated by direct effects on the ischaemic myocardium.
In: Kimchi, A, (ed.)
Advances in Heart Disease.
(pp. 271 - 275).
MEDIMOND S R L
1) Does chronic statin treatment limit infarct and 2) is acute treatment beneficial with chronic therapy. Rats were gavaged daily for two weeks with 1% methylcellulose or atorvastatin 20 mg/kg, 40mg/kg or 80 mg/kg, their hearts isolated and subjected to 35 minutes of ischemia (Langendoff) and 120 minutes reperfusion. 2 further groups' receiving 20mg/kg and 80 mg/kg atorvastatin gavage were reperfused with 50mmol/ I of atorvastatin for the first 15 minutes. Atorvastatin given chronically did not limit infarct size compared to controls (I/R ratio 54.6%+/- 6.4%) at 20mg/kg, 40mg/kg or 80mg/kg (l/R ratios 58.4%+/- 3.3%, 42.4%+/- 8.5% and 58.4% +/- 5.1% respectively). Atorvastatin 50 mu mol/l produced significant reduction in infarct size (p < 0.05) after chronic gavage with 20mg/kg and 80mg/kg of atorvastatin (I/R ratio 25.67%+/- 5.4% and 24%+/- 6.6% respectively). Chronic treatment with statins does not directly protect the myocardium. Further acute statin at reperfusion protects despite chronic treatment.
|Title:||The beneficial effects of chronic statin treatment are not mediated by direct effects on the ischaemic myocardium|
|Event:||12th World Congress on Heart Disease|
|Dates:||2005-07-16 - 2005-07-19|
|Keywords:||COA REDUCTASE INHIBITORS, CORONARY-HEART-DISEASE, INFARCT SIZE, SIMVASTATIN, PRAVASTATIN, ATORVASTATIN, PRETREATMENT, REPERFUSION, PREVENTION, PROTECTION|
|UCL classification:||UCL > School of Life and Medical Sciences
UCL > School of Life and Medical Sciences > Faculty of Population Health Sciences
UCL > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute of Cardiovascular Science
Archive Staff Only